title: YKL-40--an emerging biomarker in cardiovascular disease and diabetes.
abstract: Several inflammatory cytokines are involved in vascular inflammation resulting in endothelial dysfunction which is the earliest event in the atherosclerotic process leading to manifest cardiovascular disease. YKL-40 is an inflammatory glycoprotein involved in endothelial dysfunction by promoting chemotaxis, cell attachment and migration, reorganization and tissue remodelling as a response to endothelial damage. YKL-40 protein expression is seen in macrophages and smooth muscle cells in atherosclerotic plaques with the highest expression seen in macrophages in the early lesion of atherosclerosis. Several studies demonstrate, that elevated serum YKL-levels are independently associated with the presence and extent of coronary artery disease and even higher YKL-40 levels are documented in patients with myocardial infarction. Moreover, elevated serum YKL-40 levels have also been found to be associated with all-cause as well as cardiovascular mortality. Finally, YKL-40 levels are elevated both in patients with type 1 and type 2 diabetes, known to be at high risk for the development of cardiovascular diseases, when compared to non-diabetic persons. A positive association between elevated circulating YKL-40 levels and increasing levels of albuminuria have been described in patients with type 1 diabetes indicating a role of YKL-40 in the progressing vascular damage resulting in microvascular disease. This review describes the present knowledge about YKL-40 and discusses its relation to endothelial dysfunction, atherosclerosis, cardiovascular disease and diabetes and look ahead on future perspectives of YKL-40 research.
authors.affiliation: Dept of Internal Medicine, Center of Endocrinology and Metabolism, Copenhagen University Hospital Herlev, Denmark. cnr@dadlnet.dk
authors.forename: Camilla N
authors.initials: CN
authors.lastname: Rathcke
authors.forename: Henrik
authors.initials: H
authors.lastname: Vestergaard
mesh_terms: D054392:Adipokines; D050197:Atherosclerosis / Q000276:immunology / Q000503:physiopathology; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000276:immunology* / Q000401:mortality / Q000503:physiopathology; D000071451:Chitinase-3-Like Protein 1; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000276:immunology* / Q000401:mortality / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000276:immunology* / Q000401:mortality / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000276:immunology / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000276:immunology / Q000503:physiopathology; D006023:Glycoproteins / Q000097:blood*; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D037102:Lectins / Q000097:blood*; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D054392:Adipokines; D015415:Biomarkers; C084533:CHI3L1 protein, human; D000071451:Chitinase-3-Like Protein 1; D006023:Glycoproteins; D018836:Inflammation Mediators; D037102:Lectins